Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · PGIM (Prudential)

PGIM Jennison Health Sciences Fund Class C (PHLCX)

Ticker PHLCX · · Holdings as of May 29, 2026

Expense ratio
1.97%$197/yr per $10k
5-yr return
+5.8%annualized
1-yr return
+17.5%as of Dec 2024
Net assets
$1.4Ball share classes
Holdings
55

Bottom line

Is PHLCX a good fund? The bottom line

PHLCX is the Class C share class of PGIM Jennison Health Sciences Fund, an actively managed health care sector mutual fund from PGIM (Prudential).

Annual fees run 1.97% — about $197 a year on every $10,000 invested, more expensive than 94% of health care sector funds we track.

It returned +17.5% over one year, +5.8% a year over five years, +8.7% a year over ten (as of Dec 31, 2024, per its prospectus).

With $1.4 billion in net assets and 55 holdings, its largest position is Eli Lilly & Company (17.3%) and the top 10 make up 52.6% of the portfolio.

The closest lower-cost alternative we found is PRHSX (0.83%, 52% top-holdings overlap).

What stands out

  • 5-year return beat 71% of category peers
  • No front-end sales load

What to watch

  • Expensive for its category (1.97%)
  • Concentrated: top 10 holdings are 52.6% of assets
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What PHLCX invests in

The investment objective of the Fund is long-term capital appreciation .

The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of health sciences companies, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the Health Care sector. The group of industries in which the Fund concentrates its investments is known as its sector. The term investable assets refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions. The Fund invests in securities of…

From the fund's prospectus (filed Jan 28, 2026).

PHLCX performance

Average annual total returns
1 yr5 yr10 yr
PHLCX+17.5%+5.8%+8.7%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full PHLCX performance history →

What PHLCX costs

On a $10,000 investment, PHLCX's 1.97% expense ratio costs about $197 a year. The prospectus estimates $2,084 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full PHLCX fee table →

PHLCX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY17.35%
2Merck & Company Inc MRK6.06%
3Unitedhealth Group Inc UNH5.87%
4Thermo Fisher Scientific Inc TMO4.56%
5Argenx Se ARGX3.55%
6Vertex Pharmaceuticals Inc VRTX3.37%
7Danaher Corp DHR3.28%
8Intuitive Surgical Inc ISRG3.07%
9Lonza Group Ag LONN3.02%
10Cvs Health Corp CVS2.52%

Source: SEC Form N-PORT, period ended May 29, 2026

The top 10 make up 52.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to PHLCX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
T. Rowe PricePRHSX T. Rowe Price Health Sciences Fund, Inc.0.83%52% Compare

More funds like PHLCX →

PHLCX FAQ

What is the expense ratio of PHLCX?
PHLCX's expense ratio is 1.97%, which works out to about $197 a year for every $10,000 invested. The prospectus estimates total costs of $2,084 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PHLCX a good investment?
It depends on your goals, but the data points to: 5-year return beat 71% of category peers; no front-end sales load; expensive for its category (1.97%); concentrated: top 10 holdings are 52.6% of assets; 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does PHLCX hold?
PHLCX's largest holdings are Eli Lilly & Company (17.3%), Merck & Company Inc (6.1%), Unitedhealth Group Inc (5.9%), Thermo Fisher Scientific Inc (4.6%), Argenx Se (3.6%). It holds 55 positions in total as of May 29, 2026 (SEC Form N-PORT).
What is PHLCX's 5-year return?
PHLCX returned +5.8% a year over the five years ending Dec 31, 2024, and +8.7% a year over ten years. Past performance does not guarantee future results.
Does PHLCX have a sales load?
No. PHLCX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
What is a cheaper alternative to PHLCX?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) overlaps about 52% with PHLCX and charges 0.83%.
Who manages PHLCX?
PHLCX is offered by PGIM (Prudential) through Prudential Sector Funds, Inc..